Sub-study of the main Pulmonary Fibrosis Biomarker (PFBIO) cohort (NCT02755441), recruiting patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP). Patients are included for the collection of blood samples and regular clinical data. The database and biobank will be available for studies of HP, and can be directly compared to the main PFBIO cohort, which has recruited patients with Idiopathic pulmonary Fibrosis (IPF) since 2016. Biomarkers will be assessed as diagnostic and prognostic. Further subtyping of HP, based on blood markers (including precipitins) will also be possible with the PFBIO-HP project.
Study Type
OBSERVATIONAL
Enrollment
50
Department of respiratory medicine
Hellerup, Copenhagen, Denmark
Diagnosis of HP
MDT-Diagnosis of HP
Time frame: 0 days
Exposure to inciting antigen (patient reported)
Known exposure, as reported by the patient
Time frame: 0 days
Exposure to inciting antigen (measurable)
Measurable exposure, as tested by precipitins
Time frame: 0 days
Progression free survival
Survival without progression
Time frame: 3 years
Overall survival
Survival after diagnosis
Time frame: 3 years
Quality of life questionnaires
SGRQ
Time frame: 3 years
Pulmonary function test
FVC
Time frame: 3 years
Pulmonary function test
DLCO
Time frame: 3 years
Imaging
HRCT scans
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.